Antioxidation of metabotropic glutamate receptors ligand on unilateral substantia nigral 6-hydroxydopamine-lesioned rat

Chinese Pharmacological Bulletin

Volumn 19, Issue 1, 2002, Pages 41-44

  Gu, Bing ^a   Zhang, Ying Dong ^a   Hu, Gang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidation; Glotathione; Metabotropic gtutamate receptors; Parkinson disease; Reactive oxygen species

Indexed keywords

2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; ANTIOXIDANT; ANTIPARKINSON AGENT; APOMORPHINE; BENSERAZIDE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; GLUTATHIONE; LEVODOPA; METABOTROPIC RECEPTOR; OXIDOPAMINE; PHOSPHOSERINE; REACTIVE OXYGEN METABOLITE;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DEGENERATIVE DISEASE; GLUTATHIONE METABOLISM; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA;

EID: 0037262820     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene causes autosomal recessive juvenile parkinsonism. Nature, 1998;392(6676):605-8
2. Mizuno Y. Preface to: Proceedings of the fourth international symposium on the treatment of Parkinson's disease. Parkinsonism Related Disord, 2001;7:1-2
3. Shastry BS. Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res, 2001;44:5-12
4. Gasser T. Is Parkinson's disease an inherited condition? In: Stern GM eds. Parkinson's Disease Advances in Neurology Volume 80, Philadelphia: Lippincott Williams & Wilkins, 1999:143-52
5. Greenamyre JT. Glutamatergic influences on the basal ganglia. Clin Neuropharmacol, 2001;24(2):65-70
6. Atlante A, Calissano P, Bobba A et al. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett, 2001;497:1-5
7. Heales SJ, Bolanos JP, Stewart VC et al. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta, 1999;1410(2):215-28
8. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotripic glutamate receptors. J Neurochem, 2000;75: 889-907
9. Rouse ST, Marino MJ, Bradley SR et al. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's Disease and related disorders. Pharmacolgy & Therapeutics, 2000;88:427- 35
10. 3-norepinephrine into the lateral ventricle of the rat brain. Life Sci, 1967;6(3):281-91
11. Steenvoorden DP, van Henegouwen GM. The use of endogenous antioxidants to improve photoprotection. J Photochem Photobiol B 1997;41(1-2):1-10
12. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays, 2002;24(4):308-18
13. Tolwani RJ, Jakowec MW, Petzinger GM et al. Experimental models of Parkinson's disease: Insights from many models. Lab Anim Sci, 1999;49(4):363-71
14. Grunblatt E, Mandel S, Youdim MB. MPTP and 6-hydroxydopamine-induced Neuro-degeneration as models for Parkinson's disease: Neuroprotective strategies. J Neurol, 2000;247(Suppl 2):II 95-102
15. Kidd PM. Parkinson's disease as multifactorial oxidative neurodegeneration: Implications for integrative management. Altern Med Re, 2000;5(6):502-29
16. Pellicciari R, Costantino G. Metabotropic G-protein-coupled glutamate receptors as therapeutic targets. Curr Opin Chem Biol, 1999;3:433-40
17. Tohgi H, Abe T, Saheki M et al. Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci Lett, 1995;184(1):21-4